292 related articles for article (PubMed ID: 18670301)
1. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
2. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
3. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
4. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
5. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
[TBL] [Abstract][Full Text] [Related]
6. Identification of serum proteome components associated with progression of non-small cell lung cancer.
Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
[TBL] [Abstract][Full Text] [Related]
7. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
[TBL] [Abstract][Full Text] [Related]
8. Validity of International Association for the Study Of Lung Cancer proposals for the revision of N descriptors in lung cancer.
Lee JG; Lee CY; Bae MK; Park IK; Kim DJ; Kim KD; Chung KY
J Thorac Oncol; 2008 Dec; 3(12):1421-6. PubMed ID: 19057267
[TBL] [Abstract][Full Text] [Related]
9. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
Shevchenko VE; Arnotskaya NE; Zaridze DG
Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
[TBL] [Abstract][Full Text] [Related]
10. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
11. Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: association with tumor progression.
Pietrowska M; Polańska J; Suwiński R; Wideł M; Rutkowski T; Marczyk M; Domińczyk I; Ponge L; Marczak L; Polański A; Widłak P
Int J Oncol; 2012 Jan; 40(1):148-56. PubMed ID: 21894432
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the tumor, node, metastasis classification of lung cancer.
Nakamura S; Fukui T; Taniguchi T; Usami N; Kawaguchi K; Ishiguro F; Hirakawa A; Yokoi K
J Thorac Oncol; 2013 Dec; 8(12):1551-7. PubMed ID: 24389437
[TBL] [Abstract][Full Text] [Related]
13. Mass spectrometric identification, characterization and validation of the haptoglobin β-chain protein as a lung cancer serum biomarker.
Ayyub A; Saleem M; Musharraf SG; Naz M; Tariq A; Hashmi N
Mol Med Rep; 2015 Sep; 12(3):3755-3762. PubMed ID: 26005016
[TBL] [Abstract][Full Text] [Related]
14. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
15. Use of the proposals of the international association for the study of lung cancer in the forthcoming edition of lung cancer staging system to predict long-term prognosis of operated patients.
Rena O; Massera F; Robustellini M; Papalia E; Delfanti R; Lisi E; Pirondini E; Turello D; Casadio C
Cancer J; 2010; 16(2):176-81. PubMed ID: 20404615
[TBL] [Abstract][Full Text] [Related]
16. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers.
Rathinam S; Ward DG; James ND; Rajesh PB
Interact Cardiovasc Thorac Surg; 2011 Jul; 13(1):3-6. PubMed ID: 21525028
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
Yildiz PB; Shyr Y; Rahman JS; Wardwell NR; Zimmerman LJ; Shakhtour B; Gray WH; Chen S; Li M; Roder H; Liebler DC; Bigbee WL; Siegfried JM; Weissfeld JL; Gonzalez AL; Ninan M; Johnson DH; Carbone DP; Caprioli RM; Massion PP
J Thorac Oncol; 2007 Oct; 2(10):893-901. PubMed ID: 17909350
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
20. [Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing non-small cell lung cancer patients from healthy people].
Yang SY; Xiao XY; Zhang WG; Sun XZ; Zhang LJ; Zhang W; Zhou B; Yang DC; He DC
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jan; 29(1):31-4. PubMed ID: 16638298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
